OT 58Alternative Names: OT-58
Latest Information Update: 28 Jul 2016
At a glance
- Originator Orphan Technologies
- Class Enzymes
- Mechanism of Action Enzyme replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Homocystinuria
Most Recent Events
- 28 Jul 2016 Preclinical trials in Homocystinuria in Switzerland (unspecified route)